GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Capex-to-Operating-Cash-Flow

Australian Clinical Labs (ASX:ACL) Capex-to-Operating-Cash-Flow : 0.05 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Australian Clinical Labs's Capital Expenditure for the six months ended in Dec. 2023 was A$-3.82 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was A$73.53 Mil.

Hence, Australian Clinical Labs's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.05.


Australian Clinical Labs Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Australian Clinical Labs's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Capex-to-Operating-Cash-Flow Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23
Capex-to-Operating-Cash-Flow
- 0.06 0.08 0.05

Australian Clinical Labs Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial 0.05 0.13 0.06 0.04 0.05

Competitive Comparison of Australian Clinical Labs's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Australian Clinical Labs's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Australian Clinical Labs's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Capex-to-Operating-Cash-Flow falls into.



Australian Clinical Labs Capex-to-Operating-Cash-Flow Calculation

Australian Clinical Labs's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-6.934) / 143.681
=0.05

Australian Clinical Labs's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-3.823) / 73.532
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Australian Clinical Labs  (ASX:ACL) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Australian Clinical Labs Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Australian Clinical Labs (ASX:ACL) Business Description

Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines